Contact Us | info@thewtfc.org |

 

... in this life, no one really knows what tomorrow will bring!




Shari Goldsmith

President of

 

The WTFC

 

 


Please help Us Fund the Research to Find the Cure!







Contributions


The WTFC is proud to support
these leading research facilities:


Sloan Kettering Memorial Hospital
Johns Hopkins University
The City of Hope
The Feinstein Institute for Medical Research Washington University Medical Center
NYU Langone Medical Center
UNC Lineberger Cancer Center
The Basser Research Center for BRCA1 & 2
The Mayo Clinic
MD Anderson Cancer Center
Dana Farber Cancer Institute
The Cold Spring Harbor Laboratory
Massachusetts General Cancer Center
Tennessee State University
Illinois State University
United Methodist Hospital Foundation
Duke Cancer Institute
UCSF Foundation
University of North Texas

 

June - October 2016


The WTFC is proud to announce
$40,000 in contributions have been made to:

Dr. David Spector - Cold Spring Harbor Labs
http://www.life.illinois.edu/shapiro/publications.html

Dr. Jacqueline Bromberg - MSKCC
https://www.mskcc.org/research-areas/labs/jacqueline-bromberg

Dr. Dorothy Sipkins - Duke University Medical Center
http://www.baltimoresun.com/health/breastcancer/bs-hs-breast-cancer-test-20141004-story.html#page=

Dr. Kornelia Polyak - Dana Farber Cancer Institute
http://polyaklab.dfci.harvard.edu

Dr. Andrei Goga - UCSF Foundation
https://www.eurekalert.org/pub_releases/2016-05/udod-agu051116.php

Dr. Ron Mittler - University of North Texas
http://dfw.cbslocal.com/2016/09/14/unt-researchers-make-breast-cancer-breakthrough/

Dr. Leisha Emens - Johns Hopkins Kimmel Cancer Center
http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/breast_
cancer_program/breast_cancer_vaccine.html


Novemeber 9 2015

The WTFC is proud to announce a
$5,000 contribution has been made to:

Dr. Priscilla Brastianos at
Massachusetts General Hospital
in support of her metastatic breast cancer research.

http://www.dfhcc.harvard.edu/insider/member-detail/member/priscilla-kaliopi-brastianos-md/

June 11 2015


The WTFC is proud to announce
$25,000 in contributions have been made to:

Dr. David Shapiro - Illinois State University
http://www.life.illinois.edu/shapiro/publications.html

Dr. Jacqueline Bromberg - MSKCC
https://www.mskcc.org/research-areas/labs/jacqueline-bromberg

Dr. Ben Ho Park - Johns Hopkins Medicine
http://www.baltimoresun.com/health/breastcancer/bs-hs-breast-cancer-test-20141004-story.html#page=1

Dr. Erica Mayer - Dana Farber Cancer Institute
http://www.hematologyandoncology.net/index.php/archives/april-2015/inhibition-of-cyclin-dependent-kinases-4-and-6-in-breast-cancer/

Dr. Haifa Shen - Houston Methodist Hospital
http://www.houstonmethodist.org/haifashen



January 27 2015

The WTFC is proud to announce
a $5000 contribution has been made to:
Dr. Venkataswarup Tiriveedhi
At Tennessee State University

In support of his research determining the critical role of
chronic inflamation and breast cancer development and progression



October 16 2014

The WTFC is proud to announce
a $5000 contribution has been made to:
Dr. Shaymala Maheswaren
At Mass General Cancer Center

In support of her research in metastatic Breast Cancer

June 15 2014


The WTFC is proud to announce
$16,500 in contributions have been made to:

Dr. Nicholas Tonks at The Cold Spring Harbor Laboratory, Dr. Gregg Semenza at Johns Hopkins Medicine and Dr. Jacqueline Bromberg at Memorial Sloane Kettering Cancer Center.

April 14 2014

The WTFC is proud to announce
a $5000 contribution has been made to:
Dr. Eric Winer
At Dana Farber Cancer Institute

In support of his early stage and metastatic Breast Cancer vaccine research.

November 4 2013

The WTFC is proud to announce
a $5000 contribution has been made to:



Dr. Elizabeth Mittendorf
At MD Anderson Cancer Center

in support of her Breast Cancer Vaccine Research in
Node- Positive and High -Risk Node- Negative, Breast Cancer Patients to prevent Recurrence.

April 9 2013

The WTFC is proud to announce
a $5000 contribution has been made to:



Dr. James Ingle
At The Mayo Clinic

In support of it's research in cancer prevention, early detection
and treatment to save women's lives!

December 21 2012

The WTFC is proud to announce
a $5000 contribution has been made to:

The Basser Research Center for BRCA1 & 2
under the direction of Dr. Susan Domchek

In support of it's research in cancer prevention, early detection
and treatment to save women's lives!

October 9 2012

The WTFC is proud to announce
a $5000 contribution has been made to:


Dr. Charles Perou
At UNC Lineberger School of Medicine

In findings that are fundamentally reshaping the scientific
understanding of breast cancer, researchers have identified
four genetically distinct types of breast cancer. And within
those types, they found hallmark genetic changes that are
driving many cancers

March 7 2012

The WTFC is proud to announce
a $5000 contribution has been made to:

Dr. Robert Schneider
At NYU School of Medicine

Dr. Schneider's research seeks to develop
novel therapies for the treatment of
metastatic breast cancer by studying
and targeting its cancer stem cells.

November 29 2011

The WTFC is proud to announce
a $5000 contribution has been made to:

Dr. Sara Sukumar
At Johns Hopkins University



October 13 2011

The WTFC is proud to announce
a $5000 contribution has been made to:

Dr. William
Gillanders and his team at
The Washington University
School of Medicine

My area of research is immunology, and one thing that we are working on is the interplay between the immune system and breast cancer. I’m personally excited about the development of several different breast cancer vaccines. It has been a goal for many years to try to design tumor vaccines and specifically, breast cancer vaccines. I would say that in the last decade we’ve made a huge amount of progress towards that goal. We have a much better understanding of the immune system, how and why vaccines work and when it would be most appropriate to use them.

We have several breast cancer vaccines in the pipeline for clinical trial. It’s very promising that someday we might be able to use breast cancer vaccines as an adjunct to some of the other treatment modalities that are already in use.

The current vaccines are being used in trial for patients who are already diagnosed with breast cancer. In the future, we might be able to use the vaccines to prevent breast cancer. We’re not quite there yet, but certainly, that is one of the long-term goals of developing a vaccine. So, a woman who is identified to be high risk for developing breast cancer might be a potential candidate for the vaccine. That’s probably ten years away, but it’s one of the goals we are working towards.

December 20 2010

The WTFC is proud to announce
a $5000 contribution has been made to:

The Feinstein Institute for Medical Research
of the North Shore-LIJ health System

Breast and Ovarian Cancer Specimen Bank
Investigators at The Feinstein Institute for Medical Research recently began collaborating with North Shore-LIJ Health System oncologists on a potentially life-changing new study: a Breast and Ovarian Cancer Specimen Bank. Aimed at improving survival rates for women with either type of cancer, the study is the first of its kind and is being led by Dr. Annette Lee at The Feinstein Institute, Dr. John Lovecchio and Dr. Andrew Menzin at North Shore University Hospital, and Dr. Iuliana Shapira and Dr. Richard Gralla at the Monter Cancer Center.

For sufferers of breast and ovarian cancer, early detection is the key to survival. In fact, when diagnosed while still localized, the five-year survival rate is 98.3 percent for a breast cancer patient and over 90 percent for an ovarian cancer patient. Unfortunately, current methods of early detection are not effective until a tumor cell mass has formed, which may be years after the initial onset of the disease. Through the Breast and Ovarian Cancer Specimen Bank, researchers are collecting blood and tissue samples from women who have or are suspected to have either type of cancer. These samples will then be used as a resource to discover and validate new biomarkers for early detection, prediction of disease course and outcome, treatment response and risk of early relapse.



November 2010

The WTFC is proud to announce
a $5000 contribution has been made to:

Breast cancer research at Memorial
Sloan-kettering Cancer Center!!!!

December 2009

The WTFC is proud to announce
a $3000 contribution has been made to:

City of Hope
Dr. Melanie Palomares's Research Fund

Scientists are developing a blood test to detect breast cancer early, when it can be most successfully treated. This test could be useful for the initial diagnosis of breast cancer and for the early detection of breast cancer recurrence. Over the next five years, researchers led by Melanie Palomares, M.D., will gather blood cell specimens from women with invasive breast cancer, as well as women with ductal carcinoma in situ and benign breast disease. Dr. Palomares will study each blood cell sample in search of messages only expressed by breast cancer cells.

October 2009

The WTFC is proud to announce
a $3000 contribution has been made to:

Johns Hopkins University
Dr. Ben Ho Park's Research Fund

Our laboratory is using genetic based approaches so that we can find
better ways to prevent, diagnose and treat breast cancers. We do this using sophisticated genetic models that recapitulate genes known to cause breast cancer as well as genes that are responsible for drug resistance. For example, we recently discovered that the PIK3CA
gene is the most frequently mutated gene in human breast cancers,
and we are currently developing targeted therapies for breast cancers that contain this mutantgene. We also study other aspects of breast cancer therapy including estrogenreceptor signaling and genes that confer resistance to hormonal therapies.  A new area of active research in our lab is to find genetic factors that may or may not place women at higher risk. Using patient samples from families with ahistory of breast cancer but without BRCA1or BRCA2 mutations,wehave begun to analyze what other genes contributeto breast cancers within these families.  In addition, in families witha known BRCA1 or BRCA2 mutation, we are also studying other genes besides BRCA1 and BRCA2 that  areinvolved with cases of breast and ovarian cancers that occur in these families. The work supported by The WTFC will further our  understanding about inherited markers of risk and allow us to identify new molecular targets infamilial and sporadic forms of breast cancer.

January 2009

The WTFC is proud to announce it's first contribution of
$3000 has been made to:

Memorial Sloan Kettering Cancer Center
Dr. Jacqueline Bromberg Research Fund

My research has led to a number of important discoveries related to the nature and treatment of metastatic breast cancer. Metastatic breast cancer is a complex process which couples the immune system to creating hospitable environments in the lung, bone and liver for breast cancer cells to thrive. Of recent interest is the discovery that within a primary breast tumor, only a tiny subset of cancer cells (cancer stem cells) have the capacity to metastasize and grow in different locations (lung, bone and liver).

In order to eradicate metastatic disease we have to understand the mechanisms by which this occurs. We have discovered that a molecule known as interleukin-6 (IL-6) is the critical link between the immune system and cancer progression.  In addition, IL-6 is also produced to high levels by breast cancer stem cells which have the capacity to metastasize. Furthermore, we have shown that increasing the levels of IL-6 in a cancer cell can mediate its transformation from a "dormant" cancer to one capable of rapidly proliferating in the lung. Importantly, inhibiting this molecule not only stops the spread of cancer cells but also inhibits their growth.

We are aggressively pursuing our findings experimentally by coupling traditional chemotherapies to these novel IL-6 inhibitors and determining the most effective way of delivering these compounds such that they obviate resistance and ultimately eliminate this disease.

As a consequence of our findings we are launching a clinical trial using inhibitors of IL-6 and are extremely optimistic that this therapy, which not only targets the breast cancer stem cell but also the immune cells which mediate metastatic spread and growth, will effectively eradicate metastatic disease.



Please help us fund the the research to find the cure!

Donate Now!

Your contributions are tax- deductible
to the extent provided by law!

Well, I was lucky, I tested negative for the BRCA genes!.....my story


Find Us On Facebook!